ACCELERATE Multi-Stakeholder Platform

What ACCELERATE Multi-Stakeholder Platform does

ACCELERATE is an international multi-stakeholder non-profit platform established in 2012 and headquartered in Brussels, Belgium (VAT BE0733.539.041, co-located with BLSI), that accelerates drug development for children and adolescents with cancer. The organization operates as a neutral convening and coordination layer, running Paediatric Strategy Forums in collaboration with the EMA and FDA, an Annual Conference in Brussels, a portfolio of Working Groups (FAIR Trials, Fit For Filing, Patient Reported Outcomes, Long-Term Follow-Up, International Collaboration, Reviving Deprioritized Assets), the ALADDIN Educational Programme, Impact Forums, the Child-First Workshop, and a Resources hub of peer-reviewed publications and policy materials. Its core technology is a hybrid digital-plus-event platform that combines in-person convenings in European and North American venues with virtual/online participation, an online educational platform (ALADDIN with Ask-The-Expert Forum), and structured working-group collaboration tools including the FAIR Trials e-learning modules, investigator/sponsor toolkit, and FAIR for AYA stamp.

The platform serves four primary stakeholder segments — pediatric cancer patients and families, academic pediatric oncologists and researchers, biopharmaceutical companies, and regulatory/HTA authorities (EMA, FDA, TGA, Health Canada, PMDA) — engaging each as an equal partner to address systemic barriers including the up-to-17-year delay between adult and pediatric drug approvals and the exclusion of adolescents from adult oncology trials. As a non-profit, ACCELERATE generates no fee revenue from participation; its funding model rests on multi-tier partnerships (strategic, champion, impact, mission, supporting) anchored by the Andrew McDonough B+ Foundation and LifeArc, supplemented by charitable donations through a Cognito Forms page and project-based EU grants (notably Erasmus+ for ALADDIN). The organization has organized 16+ Paediatric Strategy Forums since 2017 with 1,019 cumulative participants covering 134 products, holds formal recognition from EMA and FDA, is registered in the EU Transparency Register, and is GDPR-compliant with data hosted in Belgium. It maintains a small distributed operating model with regular engagement across European and international stakeholders.

Name

ACCELERATE Multi-Stakeholder Platform

Legal name

ACCELERATE

Website

https://accelerate-platform.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

ACCELERATE is a Brussels-based international non-profit platform founded in 2012 that convenes pediatric cancer patients and families, academic clinicians, biopharmaceutical companies, and regulatory authorities as equal partners to accelerate drug development for children and adolescents with cancer.

Ownership category

akta.pro rank

Product category

Pediatric Oncology Drug Development Collaboration

NAICS

Educational Support Services (61171)

SIC

Services-Educational Services (8200)

akta.pro primary industry

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC)

Keywords

• Pediatric oncology drug development
• Multi-stakeholder collaboration
• Regulatory science training
• Clinical trial acceleration
• Childhood cancer research

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Partnership and Sponsorship Revenue: ACCELERATE receives financial and operational support from strategic partners, champion partners, impact partners, mission partners, and supporting partners. These partnerships provide transformational funding that enables the organization to serve as a global forum for pediatric oncology stakeholders.
2. Donations: The organization accepts donations through its Cognito Forms donation page to support core activities and events.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

ACCELERATE is an international non-profit multi-stakeholder platform that convenes pediatric cancer patients and parents, academic pediatric oncologists, researchers, biopharmaceutical companies, and regulatory authorities to accelerate drug development for children and adolescents with cancer. It operates through a portfolio of convening products including Annual Conferences, Paediatric Strategy Forums, specialized Working Groups, Impact Forums, the ALADDIN Educational Programme, and workshops, producing peer-reviewed publications, regulatory recommendations, and educational resources.

Product overview

ACCELERATE is a multi-stakeholder non-profit platform that brings together patients, parents, academic paediatric oncologists, researchers, biopharma representatives, and regulatory authorities as equal partners to accelerate innovation in drug development for children and adolescents with cancer. The platform operates as a coordinated suite of products including Annual Conferences, Paediatric Strategy Forums, Working Groups (FAIR Trials, Fit for Filing, Patient Reported Outcomes, Long-Term Follow-Up, International Collaboration, Reviving Deprioritized Assets), the ALADDIN Educational Programme, Impact Forums, and Workshops. Together, these offerings facilitate multi-stakeholder dialogue, knowledge-sharing, regulatory engagement, and collaborative research to address systemic barriers in paediatric oncology drug development.

Differentiator

Problem solved

Functional benefit

Brands

• ALADDIN: Educational programme on strategic and regulatory science in paediatric oncology drug development, created to foster expertise and strengthen multi-stakeholder collaboration. Includes training courses, 360-degree rotation at EMA and pharmaceutical companies, research fellowships, and an online educational platform.
• FAIR Trials
• Fit For Filing (FFF)
• Patient Reported Outcomes (PROs)
• Reviving Deprioritized Assets
• Logbook

Products and services

• Annual Conference Annual in-person and virtual conference held in Brussels offering discussion, knowledge-sharing, networking, and engagement with the international multi-stakeholder community. Speakers present clinical/preclinical pediatric oncology research, evolutions in the regulatory landscape, and key challenges in accelerating development of new therapies for children and adolescents with cancer.
• Paediatric Strategy Forums Multi-stakeholder meetings organized in collaboration with EMA and FDA where strategies regarding new drug development are discussed on specific topics, facilitating prioritisation to better meet patient needs and increase feasibility of paediatric developments.
• Working Groups Research initiatives exploring specific paediatric oncology challenges and proposing solutions through specialized groups including FAIR Trials (age-inclusive research), Fit For Filing (academic-industry collaborative trials), Patient Reported Outcomes, Long-Term Follow-Up, International Collaboration, and Reviving Deprioritized Assets.
• ALADDIN Educational Programme Educational programme on strategic and regulatory science in paediatric oncology drug development, offering a transversal training course, 360-degree multi-stakeholder rotation at EMA and pharmaceutical companies, research fellowship, and free online educational training platform.
• Impact Forums Specialized forums focused on specific therapeutic targets or drug classes, such as the BCL2 Impact Forum, bringing together academic experts and regulators to discuss development strategies and evidence needed for paediatric cancer applications.
• Child-First Workshop Workshop addressing challenges of conducting first-in-child clinical trials of anti-cancer drugs that advance to clinic without prior adult cancer trial data, developing shared frameworks for responsible, efficient, and globally-coordinated child-first drug development.
• Resources Comprehensive resource hub including scientific publications, work plans and reports, educational webinars, policy and regulatory information, and media coverage related to paediatric oncology drug development.

Quantifiable outcome

• 16 Paediatric Strategy Forums organized since 2017 with 1,019 total participants and 134 products discussed
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core, major and supporting.

• Andrew McDonough B+ (Be Positive) FoundationcoreStrategic or Co-development PartnerStrategic partner providing transformational support enabling ACCELERATE to serve as the only global forum where all stakeholders work as equal partners. The foundation honors Andrew McDonough and provides financial and emotional support to families of children with cancer while funding cutting-edge childhood cancer research.
• LifeArccoreStrategic or Co-development PartnerChampion partner that leads sector-wide transformation through major support of ACCELERATE's collaborative platform. Their investment powers international convenings, regulatory engagement, and strategic discussions around innovative trial design.
• Solving Kids Cancer UKmajorStrategic or Co-development PartnerMission partner demonstrating sustained commitment to transforming pediatric oncology drug development. Their support enables critical stakeholder convenings and ensures patient advocacy voices shape research priorities.
• KikamajorStrategic or Co-development PartnerMission partner supporting ACCELERATE's mission to transform pediatric oncology drug development and ensure patient advocacy representation in drug development conversations.
• European Society for Paediatric Oncology (SIOPE)majorStrategic or Co-development PartnerKey partner in the ALADDIN consortium providing educational expertise and representing the European pediatric oncology community in collaborative drug development initiatives.
• Innovative Therapies for Children with Cancer (ITCC)majorStrategic or Co-development PartnerPartner in ALADDIN consortium and FAIR Working Group coordination, representing academic pediatric oncology research networks across Europe.
• CCI EuropemajorStrategic or Co-development PartnerThe biggest pan-European childhood cancer parents' and survivors' organization partnering in ALADDIN consortium to ensure patient advocate perspectives in educational programs.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerAssociated partner in ALADDIN consortium and active collaborator in organizing Paediatric Strategy Forums. EMA and its Paediatric Committee (PDCO) follow ACCELERATE's FAIR initiative closely and support age-inclusive research efforts.
• U.S. Food and Drug Administration (FDA)coreStrategic or Co-development PartnerActive participant in Paediatric Strategy Forums providing regulatory input. FDA recommends inclusion of adolescent patients in disease- and target-appropriate adult oncology clinical trials to enable earlier access to investigational drugs.
• RochemajorStrategic or Co-development PartnerALADDIN consortium partner providing valuable input both in content and experts, as well as offering innovative mobility opportunities for researchers. Supports FAIR Trials initiative and participates in Long-Term Follow-Up Working Group.
• SanofimajorStrategic or Co-development PartnerALADDIN consortium partner contributing content expertise and supporting educational program development for pediatric oncology regulatory science.
• Gustave Roussy (School of Cancer Sciences)majorStrategic or Co-development PartnerALADDIN consortium partner providing training education expertise. Hosts working group secretariat functions and serves as a key academic center for pediatric oncology research.
• Heidelberg UniversitysupportingStrategic or Co-development PartnerALADDIN consortium partner leading the design of courses on strategic/regulatory science in pediatric oncology drug development.
• Universitat Autònoma de BarcelonasupportingStrategic or Co-development PartnerALADDIN consortium partner contributing educational expertise in the design of pediatric oncology drug development training courses.
• The Evan FoundationsupportingStrategic or Co-development PartnerCommunity partner contributing to ACCELERATE's mission to transform pediatric oncology drug development and strengthen the global network of advocates and researchers.
• Turn It GoldsupportingStrategic or Co-development PartnerCommunity partner supporting ACCELERATE's initiatives to ensure children with cancer have access to collaborative advocacy and research.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/accelerate-multi-stakeholder-platform

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACCELERATE Multi-Stakeholder Platform